4,189 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by Simplicity Solutions LLC

Simplicity Solutions LLC bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,189 shares of the company’s stock, valued at approximately $234,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of 10x Genomics by 56.4% in the third quarter. FMR LLC now owns 12,666,998 shares of the company’s stock worth $522,514,000 after buying an additional 4,565,400 shares during the last quarter. BlackRock Inc. increased its holdings in shares of 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after purchasing an additional 1,138,358 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of 10x Genomics by 4.2% in the third quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock worth $367,270,000 after buying an additional 354,921 shares in the last quarter. Sands Capital Management LLC boosted its stake in 10x Genomics by 10.2% during the second quarter. Sands Capital Management LLC now owns 4,120,269 shares of the company’s stock valued at $230,076,000 after buying an additional 382,501 shares during the last quarter. Finally, ARK Investment Management LLC grew its holdings in 10x Genomics by 35.0% during the 4th quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock valued at $226,150,000 after buying an additional 1,047,827 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at approximately $42,367,020.93. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now owns 855,381 shares of the company’s stock, valued at approximately $42,367,020.93. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Justin J. Mcanear sold 1,865 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $86,424.10. Following the sale, the chief financial officer now directly owns 95,240 shares of the company’s stock, valued at approximately $4,413,421.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,959 shares of company stock worth $592,806. Company insiders own 10.65% of the company’s stock.

Analysts Set New Price Targets

TXG has been the subject of a number of research reports. Stifel Nicolaus lowered their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Barclays decreased their target price on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, 10x Genomics has a consensus rating of “Moderate Buy” and an average target price of $60.22.

10x Genomics Price Performance

NASDAQ TXG opened at $27.94 on Friday. The company’s 50-day simple moving average is $39.76 and its two-hundred day simple moving average is $42.95. 10x Genomics, Inc. has a one year low of $26.75 and a one year high of $63.57.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The business had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. The business’s revenue was up 17.8% on a year-over-year basis. Analysts predict that 10x Genomics, Inc. will post -1.47 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.